You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023560044
Dec 2023205012
Jan 2024188024
Feb 2024118014
Mar 202414405
Apr 2024136011
May 2024138010
Jun 202412908
Jul 2024206018
Aug 2024264025
Sep 2024153015
Oct 202431009
Nov 2024184019
Dec 2024204014
Jan 2025186018
Feb 202591016
Mar 20250012
Apr 20250026
May 20250015
Jun 2025005
Total32160320